A critical inflection year marked by accelerating losses and near-exhaustion of liquidity as the company advanced its lead asset toward regulatory submission, though positive Phase IIb survival data provides a path to potential approval.
Key takeaways
Operating Income was -$28.7M (-321.3%)
Net Income was -$28.8M (-223.7%)
Eps was $-0.98 (-11.4%)
Full analysis
Clinical Milestones and Regulatory Advancement Driving Cost Surge
Critical Liquidity Position and Going Concern Risks